Sterling Pharma Solutions Confirms ADC Bio Acquisition

BioPharm International Editors

Sterling Pharma Solutions has acquired ADC Biotechnology, a bioconjugation development services business specializing in antibody drug conjugates.

Sterling Pharma Solutions has announced its acquisition of ADC Biotechnology, a bioconjugation development services business specializing in antibody drug conjugates (ADCs), in an April 6, 2021 press release. The acquisition follows the strategic investment by contract development and manufacturing organization (CDMO), Sterling, in December 2020.

Through the acquisition, the ADC Bio facility, which is based in North Wales in the United Kingdom, will be rebranded and become part of the Sterling Pharma Solutions international network. Combining Sterling’s experience in current good manufacturing practice (CGMP) manufacturing, quality processes, and compliance, with the expertise of ADC Bio, the companies are aiming to establish a center of excellence for bioconjugation and ADC development and manufacturing services.

Financial investment is being made to support to growth of the ADC capabilities, including expansion and development of the existing bioconjugation technical services team and analytical services team (particularly in the CGMP area). Additionally, the companies plan to create CGMP bioconjugation/ADC manufacturing at the North Wales facility in 2022.

“We are delighted to confirm the acquisition of the ADC Bio business, this investment provides us with the opportunity to offer a wider portfolio of services to our customers in the fast-growing ADC and bioconjugation market, as well as providing additional services to existing ADC Bio customers,” said Kevin Cook, CEO at Sterling Pharma Solutions, in the press release. “Integrating our HPAPI [highly potent API] capabilities with the expertise already found at Deeside means that we will also be able to offer the development and manufacture of toxin linkers. This is an exciting time for both businesses as we embark on a period of growth and diversification to ensure we always stay ahead of the next innovation. I’d like to welcome all ADC Bio employees to the Sterling family.”

Alan Raymond, executive chairman of ADC Bio, added in the press release, “This is fantastic news for our employees and our customers; targeted investment in both people and processes will allow the team to continue supporting important advances in drug development with additional services, and importantly with the additional support and experience from the Sterling team.

Source: Sterling Pharma Solutions